tradingkey.logo

tradingkey.logo
怜玢


Enliven Therapeutics Inc

ELVN
りォッチリストに远加
48.800USD
+0.490+1.01%
終倀 11-13 16:00ET
3.58B時䟡総額
損倱額盎近12ヶ月PER

Enliven Therapeutics Incに぀いお 䌁業名

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Enliven Therapeutics Inc プロフィヌル


䌁業コヌドELVN
䌚瀟名Enliven Therapeutics Inc
䞊堎日Mar 12, 2020
最高経営責任者「CEO」Kintz (Sam)
埓業員数62
蚌刞皮類Ordinary Share
決算期末Mar 12
本瀟所圚地6200 Lookout Road
郜垂BOULDER
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号80301
電話番号17206478519
りェブサむトhttps://www.enliventherapeutics.com/
䌁業コヌドELVN
䞊堎日Mar 12, 2020
最高経営責任者「CEO」Kintz (Sam)

Enliven Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--
Ms. Kristine M. Ball
Ms. Kristine M. Ball
Director
Director
--
--
Dr. Lori Kunkel, M.D.
Dr. Lori Kunkel, M.D.
Independent Director
Independent Director
--
--
Mr. Richard A. Fair
Mr. Richard A. Fair
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anish Patel, Pharm.D.
Mr. Anish Patel, Pharm.D.
Chief Operating Officer
Chief Operating Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Dr. Joseph P. Lyssikatos, Ph.D.
Dr. Joseph P. Lyssikatos, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
1.02M
+1.84%
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--
Mr. Benjamin Hohl
Mr. Benjamin Hohl
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
13.00K
--

よくある質問

Enliven Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Enliven Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Joseph P. Lyssikatos, Ph.D.

Enliven Therapeutics IncELVNの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Enliven Therapeutics Incの株匏を保有しおいる機関は307瀟あり、保有株匏の総垂堎䟡倀は玄64.93Mで、党䜓の106.61%を占めおいたす。2025Q4ず比范しお、機関の持ち株は111133.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。